Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis

NCT ID: NCT02185118

Last Updated: 2014-07-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2018-07-31

Brief Summary

Sepsis is a major cause of death in intensive care units. Despite the investigators improved understanding, which has reduced the risk of dying with sepsis, the number of people who die each year continues to increase due to an overall increase in the number of cases.In our previous study, the investigators have showed that 100% oxygen or 0.5 minimum alveolar concentration (MAC) isoflurane/sevoflurane in 60% oxygen protect mouse macrophage cell line against in-vitro sepsis induced by lipopolysaccharide (LPS).

In this study, the investigator hypothesized that treatment of 100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen protected against clinical in-vitro models of sepsis induced by LPS or plasma from septic patients.

Detailed Description

100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen would inhibit increases of tumor necrosis factor (TNF)-alpha, interleukin-1beta, interleukin-6 in the cell culture supernatant after stimulation of LPS or plasma from septic patients, and also inhibit the nuclear location of nuclear factor-kappa B p65 subunit.

Conditions

Sepsis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

oxygen plus isoflurane/sevoflurane

All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.

The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.

Group Type: EXPERIMENTAL

oxygen

Intervention Type: DRUG

1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.

2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Sevoflurane

Intervention Type: DRUG

1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.

2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Isoflurane

Intervention Type: DRUG

1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.

2. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Interventions

oxygen

1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.

2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Intervention Type: DRUG

Sevoflurane

1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.

2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Intervention Type: DRUG

Isoflurane

1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.

2. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.

Intervention Type: DRUG

Other Intervention Names

100% oxygen; subanesthetic sevoflurane in 60% oxygen; subanesthetic isoflurane in 60% oxygen

Eligibility Criteria

Inclusion Criteria

• Human PBMCs were only isolated from the adult patients without sepsis/SIRS/infectious diseases.
• The plasma for induction of clinical in-vitro sepsis, was only isolated from adult patients with sepsis.

Exclusion Criteria

• Patients who had been selected for other clinical trials in the 3 months before.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Air Force Military Medical University, China

OTHER

Sponsor Role: lead

Responsible Party

Lichao Hou

M.D., Ph.D

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Lichao Hou, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Air Force Military Medical University, China

Locations

Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University,

Xi'an, Shaanxi, China

Site Status: RECRUITING

Countries

China

Central Contacts

Lichao Hou, M.D., Ph.D.

Role: CONTACT

hou2001@fmmu.edu.cn

Facility Contacts

lichao Hou

Role: primary

hou2001@fmmu.edu.cn

Other Identifiers

Chinese NSFC

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

NSFC-81171839

Identifier Type: -

Identifier Source: org_study_id